Nov 20, 2019 | METH in the news, Uncategorized
Source: Meth in the Miami Valley: Drug coming back more addictive, powerful
Feb 5, 2019 | Uncategorized
In August 2018, the DEA Intelligence Program, in conjunction with the NY/NJ High Intensity Drug Trafficking Area program and the NJ State Police Regional Operations Intelligence Center’s Drug Monitoring Initiative assessed the methamphetamine drug threat in New...
Jan 15, 2016 | Anti-METH antibody, IXT-m200, General News, Uncategorized
Little Rock, AR – InterveXion Therapeutics, a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IXT-m200, also known as ch-mAb7F9, an investigational drug candidate for the...
Jan 29, 2015 | Anti-METH antibody, IXT-m200, Anti-METH Vaccine, General News, Grants, Uncategorized
LITTLE ROCK – A University of Arkansas for Medical Sciences (UAMS) BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break...
Jan 5, 2015 | Anti-METH antibody, IXT-m200, General News, Uncategorized
The company is pleased to report publication of the results of the first human study of ch-mAb7F9. The paper was published in the journal Mabs in early November. Abstract – This first-in-human study examined the safety and pharmacokinetics of ch-mAb7F9, an...
Nov 20, 2014 | Anti-METH antibody, IXT-m200, General News, Uncategorized
A new manuscript published by UAMS describes the shortened duration of repeated METH dose effects in rats over a month following administration of mAb7F9. Abstract – This study assessed clinical scenarios of continuing monoclonal antibody (mAb) treatment for (+)-...
Recent Comments